In vitro Antifungal Effects of Berberine Against Candida spp. In Planktonic and Biofilm Conditions

被引:36
作者
Xie, Yufei [1 ]
Liu, Xiaosong [1 ]
Zhou, Peiru [1 ]
机构
[1] Peking Univ, Dept Oral Med, Sch & Hosp Stomatol, Beijing 100081, Peoples R China
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2020年 / 14卷
基金
中国国家自然科学基金;
关键词
berberine; antifungal effect; Candida spp; biofilm; INFECTIOUS-DISEASES SOCIETY; CLINICAL-PRACTICE GUIDELINE; 2016; UPDATE; SUSCEPTIBILITY; MECHANISM; EPIDEMIOLOGY; MANAGEMENT; TRENDS;
D O I
10.2147/DDDT.S230857
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purpose: Antifungal resistance associated with the extensive use of antifungals and biofilm formation presents major clinical challenges. Thus, new therapeutic strategies for fungal infections are urgently required. This study aimed to evaluate the in vitro antifungal effects of the natural bioactive alkaloid berberine against Candida spp. in planktonic and biofilm conditions. Methods: Using the CLSI M27-A3 reference method for broth dilution antifungal susceptibility testing of yeasts, the MICs for five standard strains comprised of Candida albicans (ATCC 10231, ATCC 90028), Candida krusei (ATCC 6258), Candida glabrata (ATCC 90030), Candida dubliniensis (MYA 646), and six clinical isolates (CLC1-CLC6) were tested. The 2,3-bis-(2-methoxy-4-nitro-5-sulfopheny1)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay was used to evaluate the inhibitory effects of berberine against Candida biofilms The optical density value at 490 nm was measured and illustrated using concentrationabsorbance curves. Finally, the effects were quantified by confocal laser scanning microscopy (CLSM), and 3-dimensional reconstruction was performed. The viability inhibition rates, biofilm formation, and thickness decrease rates were tested and analyzed using independentsamples t-test. The differences among the five Candida strains were analyzed using one way ANOVA. Results: The MICs for the five standard strains described above were 80, 160, 10, 20, and 40 mu g/mL, respectively, which was similar to that of the clinical isolates, suggesting the stable, broad-spectrum antifungal activity of berberine. Berberine exerted concentration-dependent inhibitory effects against Candida biofilms, which were enhanced with the maturation of Candida biofilms Berberine decreased the viability of Candida biofilms, with inhibition rates by CLSM ranging from 19.89 +/- 0.57% to 96.93 +/- 1.37%. Following 3-dimensional reconstruction, the biofilms of the berberine-treated group displayed a poorly developed architecture, and the biofilm thickness decrease rates ranged from 15.49 +/- 8.45% to 30.30 +/- 15.48%. Conclusion: Berberine exhibited significant antifungal activity in Candida spp. The results provide a useful reference for multiple Candida infections and biofilm infections associated with antifungal resistance. Therefore, berberine might have novel therapeutic potential as an antifungal agent or a major active component of antifungal drugs.
引用
收藏
页码:87 / 101
页数:15
相关论文
共 40 条
  • [11] Berberine synergy with amphotericin B against disseminated candidiasis in mice
    Han, Y
    Lee, JH
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (03) : 541 - 544
  • [12] Berberine and barberry (Berberis vulgaris): A clinical review
    Imenshahidi, Mohsen
    Hosseinzadeh, Hossein
    [J]. PHYTOTHERAPY RESEARCH, 2019, 33 (03) : 504 - 523
  • [13] In vitro antifungal activity of the berberine and its synergism with fluconazole
    Iwazaki, Renata Sayuri
    Endo, Eliana Harue
    Ueda-Nakamura, Tania
    Nakamura, Celso Vataru
    Garcia, Lourdes Botelho
    Dias Filho, Benedito Prado
    [J]. ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 2010, 97 (02): : 201 - 205
  • [14] Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008)
    Klingspor, L.
    Tortorano, A. M.
    Peman, J.
    Willinger, B.
    Hamal, P.
    Sendid, B.
    Velegraki, A.
    Kibbler, C.
    Meis, J. F.
    Sabino, R.
    Ruhnke, M.
    Arikan-Akdagli, S.
    Salonen, J.
    Doczi, I.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (01) : 87.e1 - 87.e10
  • [15] Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
    Koehler, P.
    Stecher, M.
    Cornely, O. A.
    Koehler, D.
    Vehreschild, M. J. G. T.
    Bohlius, J.
    Wisplinghoff, H.
    Vehreschild, J. J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (10) : 1200 - 1212
  • [16] Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
    Leroy, Olivier
    Bailly, Sebastien
    Gangneux, Jean-Pierre
    Mira, Jean-Paul
    Devos, Patrick
    Dupont, Herve
    Montravers, Philippe
    Perrigault, Pierre-Francois
    Constantin, Jean-Michel
    Guillemot, Didier
    Azoulay, Elie
    Lortholary, Olivier
    Bensoussan, Caroline
    Timsit, Jean-Francois
    [J]. ANNALS OF INTENSIVE CARE, 2016, 6 : 1 - 11
  • [17] Emerging and reemerging fungal infections
    Lockhart, Shawn R.
    Guarner, Jeannette
    [J]. SEMINARS IN DIAGNOSTIC PATHOLOGY, 2019, 36 (03) : 177 - 181
  • [18] Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)
    Lortholary, Olivier
    Renaudat, Charlotte
    Sitbon, Karine
    Madec, Yoann
    Denoeud-Ndam, Lise
    Wolff, Michel
    Fontanet, Arnaud
    Bretagne, Stephane
    Dromer, Francoise
    [J]. INTENSIVE CARE MEDICINE, 2014, 40 (09) : 1303 - 1312
  • [19] Montagna MT, 2014, EUR REV MED PHARMACO, V18, P661
  • [20] Candida biofilm resistance
    Mukherjee, PK
    Chandra, J
    [J]. DRUG RESISTANCE UPDATES, 2004, 7 (4-5) : 301 - 309